Effects of spironolactone on calcium and parathyroid hormone in polycystic ovary syndrome

Abstract

Aim: To investigate the effects of short-term oral intake of spironolactone on parathyroid hormone (PTH)  and calcium levels, as well as other biochemical and clinical parameters in normotensive female patients with polycystic ovary syndrome (PCOS).

Method: 32 PCOS patients were studied at baseline and three months after regular intake of a daily dose of 50 mg or 100 mg spironolactone. PTH, calcium and other biochemical tests as well as clinical parameters were evaluated at baseline and after three months.

Results: Body mass index and serum PTH levels decreased significantly after treatment (p: 0.021 and p: 0.043, respectively). Mean high-density lipoprotein was significantly decreased after treatment (p: 0.011). No significant change was observed in calcium, phosphorus, total cholesterol, triglycerides, and fasting blood glucose levels. Serum testosterone and dehydroepiandrosterone sulphate decreased significantly after 3 months of therapy (p: 0.000 and p: 0.006; respectively).

Conclusions: In our study, taking spironolactone at a dose of 100 mg/day lowered PTH levels and had a positive effect on weight loss and insulin resistance. New studies are needed to investigate the effects of treatment with spironolactone on bone and metabolism. It is recommended to monitor dyslipidemia while taking the drug.